QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patie...

Core News & Articles

Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive opti...

 prelude-therapeutics-granted-us-patent--us-12448389-b2-for-brm-targeting-compounds-and-associated-methods-of-use

https://ppubs.uspto.gov/api/pdf/downloadPdf/12448389?requestToken=eyJzdWIiOiJlZWQ3ZTE2MS1kZjI1LTQyNTktODVjNy02NmE4NGMzYWM1ZDciL...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-maintains-market-outperform-on-prelude-therapeutics-lowers-price-target-to-3

JMP Securities analyst Reni J. Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the...

 prelude-therapeutics-q1-eps-042-beats-047-estimate

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

 jmp-securities-reiterates-market-outperform-on-prelude-therapeutics-maintains-4-price-target

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and maintains $4...

 hc-wainwright--co-reiterates-buy-on-prelude-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION